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Abstract: The protein C pathway has an important function in regulating and modulating blood 
coagulation and ensuring patency of the microcirculation. Protein C deﬁ  ciency leads to macro- and 
microvascular thrombosis. Congenital severe protein C deﬁ  ciency is a life-threatening state with 
neonatal purpura fulminans and pronounced coagulopathy. Patients with heterozygous protein 
C deﬁ  ciency have an increased risk for thromboembolic events or experience coumarin-induced 
skin necrosis during initiation of coumarin therapy. Replacement with protein C concentrates is an 
established therapy of congenital protein C deﬁ  ciency, resulting in rapid resolving of coagulopathy 
and thrombosis without reasonable side effects. This article summarizes the current knowledge 
on protein C replacement therapy in congenital protein C deﬁ  ciency.
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Introduction
Protein C is part of a complex regulatory system, which has an important inﬂ  uence on 
the physiological function of hemostasis to ensure patency of the microcirculation. It 
was discovered in 1976 by Stenﬂ  o as the zymogen of an anticoagulant protein, which 
could be activated by thrombin (Stenlo 1976). The clinical importance of protein C 
became evident when Grifﬁ  n et al demonstrated an association with thromboembolic 
events (Grifﬁ  n et al 1981). Hereditary (congenital) protein C deﬁ  ciency is rare, but a 
strong risk factor for thrombosis (Bertina et al 1982). At the beginning of the 1990s 
the resistance to activated protein C was discovered, a mutation in the gene of coagula-
tion factor V, altering the inactivation of factor Va by protein Ca. This mutation occurs 
frequently in the general population and is also associated with an increased risk for 
thrombosis (Dahlbäck et al 1993; Bertina et al 1994). Acquired protein C deﬁ  ciencies 
can occur in several other diseases. Sepsis and severe infections especially were the 
center of the scientiﬁ  c interest during the previous decade (Levi et al 1997; Esmon 
2001, 2006; Faust et al 2001). It could be shown that the probability of survival of 
septic patients was correlated with their protein C activity (Fourrier et al 1992; Meesters 
et al 2000; Yan et al 2001; Macias et al 2004). Since 1988 larger amounts of protein C 
could be derived from human plasma and used for therapy of deﬁ  ciency states.
This article summarizes the current knowledge on treating congenital protein C 
deﬁ  ciency with concentrates of human protein C.
The physiology of the protein C pathway
The gene for protein C is located on chromosome 2q13-14. It is composed of 9 exons 
and 8 introns, 11 kilobases (kb) in size and homologous to the genes of other vitamin K Biologics: Targets & Therapy 2008:2(2) 286
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dependent proteins (Esmon 2003). Until now more than 230 
different mutations and polymorphisms in the protein C gene 
have been detected (Reitsma et al 1995; Reitsma 1997; http://
www.hgmd.cf.ac.uk/ac/gene.php?gene=PROC).
The protein itself is synthesized in the liver as a precur-
sor of 461 amino acids. In presence of vitamin K, gamma-
carboxylation of 9 glutamic acid (gla) residues in the 
gla-domain is performed. The mature protein is composed 
of 419 amino acids and has a molecular weight of about 62 
kD. Before secretion it is cleaved by a furin-like endoprotease 
at lys156 and arg157, resulting in a heavy and a light chain, 
connected by disulﬁ  de bonds. The gamma-carboxylated gla 
domain (amino acids 1–42) is necessary for the calcium-
mediated binding of the protein to phospholipids, but also 
to thrombomodulin and the endothelial protein C receptor 
(EPCR) (Beckman et al 1985; Dahlbäck and Stenﬂ  o 1994; 
Esmon 2003).
Protein C zymogen is activated by thrombin. Once gener-
ated during the procoagulatoric cascades, thrombin can be 
bound to thrombomodulin on the surface of endothelial cells, 
and its procoagulatoric properties are blocked. In contrast, 
bound thrombin converts protein C zymogen into an active 
serine protease by cleavage of the heavy chain at position 
arg169-leu170. The localization of protein C activation to 
the surface of endothelial cells is an important mechanism 
to avoid the formation of thrombi in the microcirculation 
(Esmon 1989; Ye et al 1999; Van de Wouwer et al 2004).
The physiological plasma concentration of protein C 
zymogen is 63 nM or 4 μg/mL; the half-life under physi-
ologic conditions is about 6–8 hours. In situations with 
increased activation of the coagulation pathways (ie, sys-
temic response to inﬂ  ammation, disseminated intravascular 
coagulation, consumption coagulopathy), this half-life can 
be considerably shortened, down to 2–3 hours, resulting in 
a relative deﬁ  ciency of protein C and the development of a 
thrombogenic state. Activated protein C (protein Ca) can be 
found in the plasma in concentrations of about 40 pM. The 
half-life of protein Ca in plasma is short (about 20 minutes). 
Once formed, it is immediately degraded by speciﬁ  c and 
unspeciﬁ  c plasmatic inactivators. The protein C inhibitor, 
α-1-protease-inhibitor, and α-2-macroglobulin are the major 
inhibitors of activated protein C.
Activated protein C has a pronounced anticoagulatoric 
function, for which another vitamin K dependent protein, 
protein S, is necessary as a cofactor: it cleaves the activated 
coagulation factors V and VIII. These homologous proteins 
serve as cofactors during blood coagulation. The inhibition 
of factors Va and VIIIa is an important regulatory mechanism, 
modulating the time course and intensity of blood coagulation 
(Esmon 1987; 1989; 2003).
Activated protein C has an indirect profibrinolytic 
effect: it binds to the plasminogen-activator inhibitor 1 
(PAI-1), resulting in an increase of the activity of tissue-type 
plasminogen activator (tPA). In addition, due to the reduced 
thrombin generation, the activation of TAFI (thrombin 
activatable ﬁ  brinolysis inhibitor) is diminished, thus resulting 
in an increased proﬁ  brinolytic potential (De Fouw et al 1988; 
Fouassier et al 2005).
Apart from its central role in regulation of coagulation 
activation, the protein C system also has an important func-
tion in modulating inﬂ  ammation, and has antiapoptotic, 
cytoprotective, and barrier stabilizing effects (Okajima 2001; 
Joyce and Grinnell 2002; Feistritzer and Riewald 2005; 
Mosnier et al 2007). Most of these effects are mediated by the 
endothelial protein C receptor (EPCR), the protease-activated 
receptor-1 (PAR-1), or crossactivation of the sphingosine 
1-phosphate receptor-1 (S1P1) (Esmon et al 1999; Riewald 
et al 2002; Brueckmann et al 2005; Feistritzer and Riewald 
2005; Mosnier et al 2007). Binding of protein Ca to EPCR 
influences gene expression profiles by blocking NFκB 
nuclear translocation, which is necessary for the produc-
tion of proinﬂ  ammatory cytokines and adhesion molecules 
(White et al 2000a).
Congenital (hereditary) protein C 
deﬁ  ciency
The hereditary protein C deﬁ  ciency states are caused by muta-
tions in the protein C gene located on chromosome 2(q13-14) 
(Online Mendelian Inheritance in Man, OMIM +176860) 
(www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176860). It 
may occur as heterozygous (only one of both chromosomes 2 
affected), homozygous (both chromosomes 2 carry the same 
mutation), or mixed heterozygous (both chromosomes 2 are 
affected, but with different mutations) (Table 1) (Greengard 
et al 1994). Until now more than 230 different mutations 
causing protein C deficiency have been described and 
published in databases (http://www.hgmd.cf.ac.uk/ac/gene.
php?gene=PROC). A review article of Reitsma summarized 
the main characteristics of these gene defects (Reitsma et al 
1995; Reitsma 1997). Missense and nonsense mutations are 
most frequent, but also splicing abnormalities, small inser-
tions or deletions, and regulatory defects have been described 
(Table 2). They may affect different parts of the gene, result-
ing in alterations of the various functions of protein C.
Type I protein C deﬁ  ciency is characterized by a parallel 
reduction of both protein C activity and antigen concentration Biologics: Targets & Therapy 2008:2(2) 287
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in the plasma. It is mainly caused by mutations in the 
hydrophobic core of protein C, causing large deletions, 
insertions, or frameshifts.
Type II deﬁ  ciency is characterized by a reduced activity of 
protein C, but a near normal antigen concentration. Mutations 
affect the active site of the enzyme, or domains responsible 
for protein-protein or protein-phospholipid interactions. 
Most of the mutations were found in exon 3 (gla-domain), 
other mutations affected arg1 (cleavage of the propeptide), 
arg169 (site of activation by thrombin), his11 (in the active 
site), or other mutations of the active site near exon 9. Type 
II deﬁ  ciencies may not only affect the function of protein 
C, but also other properties: activation of protein C, binding 
to phospholipids, to thrombomodulin, protein S, or EPCR 
(Greengard et al 1994).
Diagnosis of congenital 
protein C deﬁ  ciency
For clinical purposes, determinations of protein C activity and/
or antigen are useful and reliable for the diagnosis of protein 
C deﬁ  ciency. Only in a few cases, especially with mutations 
affecting other than the anticoagulant function of protein C, 
diagnostic problems may occur: disturbances of protein C 
activation (by mutations of the thrombin binding site) may 
cause wrong results with certain activation assays, but not 
with others (Table 3). In such cases the much more elaborate 
molecular analysis of the protein C gene may be helpful. This 
analysis from amniotic ﬂ  uid or chorion villus biopsy may also 
be considered in pregnancies with a high risk for homozygous 
protein C deﬁ  ciency of the fetus (ie, both parents heterozygous 
or consanguineous) (Barnes et al 2002).
In patients not on vitamin K antagonist therapy, the 
lower normal limit for protein C activity is reported to be 
about 0.67–0.72 IU/mL, but the levels are dependent on age. 
Protein C levels of newborns are around 30% of the adult 
levels and increase within the ﬁ  rst years of life. However, 
every coagulation laboratory should establish a local normal 
collective. Patients with protein C deﬁ  ciency can usually be 
discriminated well from normal subjects, but other possible 
reasons for decreased protein C levels (vitamin K deﬁ  ciency, 
liver disease) have to be excluded (by the determination of a 
prothrombin time assay; Pabinger et al [1992]).
Homozygous protein C deﬁ  ciency
Homozygous protein C deﬁ  ciency is rare. The incidence is 
1 per 500,000–750,000 live births. It occurs when on both 
chromosomes 2 the genes coding for protein C are affected. 
The same mutation on both chromosomes causes the classical 
homozygous deﬁ  ciency state. It occurs mainly in populations 
with frequent consanguineous marriage. Different mutations 
on the both chromosomes 2 lead to a double heterozygous 
protein C deﬁ  ciency state (Lane et al 1997).
Plasma protein C activity levels are usually very low 
(below 0.01 IU/mL). Homozygous, severe protein C deﬁ  -
ciency manifests in the ﬁ  rst days after birth as neonatal 
purpura fulminans with necrosis of the skin, severe coagu-
lopathy (disseminated intravascular coagulation), and arterial 
and venous thrombosis. These lesions have a characteristic 
morphology: they are irregularly formed, with a central hypo-
perfused or necrotic area, and a red inﬂ  ammatory border 
(Figure 1) The ﬁ  rst reports on such a state were published 
in 1983 (Branson et al 1983). Mortality without therapy is 
almost 100%. However, in some patients a less dramatic 
clinical appearance may occur, resembling an early-onset 
heterozygous deﬁ  ciency: such patients present with extensive 
venous thromboembolism. It seems that the severity of the 
clinical presentation is dependent on the residual amount 
of protein C; levels above 0.03–0.05 IU/mL are sufﬁ  cient 
to ameliorate the symptoms of purpura fulminans, but 
also the type of mutation may be important (Branson et al 
Table 1 Different manifestations of congenital protein C deﬁ  ciency
Zygosity Frequency
Type I heterozygous 76%
Type II heterozygous 12%
Type I homozygous 5%
Type II homozygous 0.6%
Type I mixed heterozygous 3%
Type II mixed heterozygous 0.6%
Type I/II mixed heterozygous 1.5%
Unknown 1.3%
Note: Analysis of 320 patients.
Table 2 Types of mutations in the protein C gene causing protein 
C deﬁ  ciency
Mutation Frequency n (%)
Missense/nonsense 170 (72.0)
Splicing 22 (9.3)
Regulatory 11 (4.7)
Small deletions 20 (8.5)
Small insertions 10 (4.2)
Small indels 1 (0.4)
Gross deletions 2 (0.8)
Gross insertions 0
Complex rearrangements 0
Repeat variations 0
Total 236
According to the Human Gene Mutation Database at Institute of Medical Genetics 
in Cardiff (http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PROC).Biologics: Targets & Therapy 2008:2(2) 288
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1983; Sharon et al 1986). Another remarkable ﬁ  nding is the 
observation that, in utero, retinal thrombosis and bleeding 
can occur, leading to blindness of the newborn (Hattenbach 
et al 1999). The fact that thrombosis occurs so late during 
pregnancy suggests the possibility of a transplacentar passage 
of some protein C, which is a rather small protein, from the 
mother to the fetus. It has further important impact on the 
management of mothers with a high probability of bearing a 
child with homozygous protein C deﬁ  ciency (Manco-Johnson 
and Nuss 1992; Barnes et al 2002).
Therapy of homozygous 
protein C deﬁ  ciency
Treatment of homozygous protein C deﬁ  ciency is performed 
primarily by substitution of the deﬁ  cient protein (Marlar 
et al 1989; Salonvaara et al 2004) (Table 4). Until 1988, 
the only sources for protein C were fresh frozen plasma, 
and prothrombin complex concentrates (which also contain 
protein C). The ﬁ  rst report of substitution therapy with a 
protein C concentrate was published in 1988 (Vukovich et al 
1988). A 10-month-old daughter of a consanguineous Arab 
family, presenting with purpura fulminans due to homozy-
gous protein C deﬁ  ciency, was treated with a plasma-derived 
concentrate containing protein C and S. All skin lesions 
resolved and the child was treated with vitamin K antagonists 
thereafter. The in vivo half-life of protein C in this child was 
Table 3 Types and diagnosis of protein C deﬁ  ciency
Deﬁ  ciency Protein C activity
(function)
Protein C antigen
(protein 
concentration)
Heterozygous
Type I decreased
(about 0.5 IU/mL)
decreased
(about 0.5 IU/mL)
Type II decreased
(about 0.5 IU/mL)
normal
Homozygous
Type I severely decreased
(0.02 IU/mL)
severely decreased
(0.02 IU/mL)
Type II severely decreased
(0.02 IU/mL)
normal/moderately 
decreased
Figure 1a Five-day-old newborn with homozygous protein C deﬁ  ciency and purpura fulminans. Irregularly formed hypoperfused or necrotic skin lesions surrounded by an 
inﬂ  ammatory border.Biologics: Targets & Therapy 2008:2(2) 289
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Figure 1b The same child 6 days after beginning of protein C replacement with Ceprotin®.
Figure 1c The same child 2 months later.   All ﬁ  gures from Dreyfus M, Masterson M, David M, et al 1995. Replacement therapy with a monoclonal antibody puriﬁ  ed protein C 
concentrate in newborns with severe congenital protein C deﬁ  ciency. Semin Thromb Haemost, 21:371–81.  Copyright © 1995. Reprinted by permission Thieme Publishers.Biologics: Targets & Therapy 2008:2(2) 290
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8.3 hours, the recovery after infusion 44%. However, this 
concentrate never reached industrial production.
The next report of protein C substitution with concentrates 
was published in 1991 (Dreyfus et al 1991). This group used 
another plasma-derived protein C concentrate (Ceprotin®, 
described below) in a child with homozygous protein C deﬁ  -
ciency and purpura fulminans. This concentrate was thereafter 
approved for the treatment of congenital protein C deﬁ  ciency. 
Until now, several reports on the use of this concentrate in 
congenital protein C deﬁ  ciency have been published (Auberger 
1992; Conard et al 1993; DeStefano et al 1993; Alhenc-Gelas 
et al 1995; Baliga et al 1995; Dreyfus et al 1995; Muller 
et al 1996; Gatti et al 2003). In almost all treated children an 
impressive response with resolution of coagulopathy and skin 
lesions had been observed. Pharmacokinetic analysis demon-
strated half-lives of 4.2–8.3 hours and recoveries of about 44% 
after infusion. Table 4 describes the modalities of dosing and 
monitoring this therapy. This concentrate may also be given as 
a subcutaneous injection (Minford et al 1996; Sanz-Rodriugez 
et al 1999; Mathias et al 2004) or continuous infusion, although 
it is not approved for these kinds of application.
Another series of patients were treated with a plasma-derived 
protein C concentrate of French origin (Protexel®) (Dreyfus 
et al 2007). Details of these patients are presented below.
Another possible source of protein C is the concentrate of 
recombinant activated protein C (drotrecogin alpha activated; 
Xigris®), which is approved only for the therapy of severe sepsis. 
However, several reports demonstrated a beneﬁ  cial effect in con-
genital purpura fulminans, too (Manco-Johnson et al 2004).
A special situation is pregnancy with a high risk for 
homozygous protein C deﬁ  ciency in the child (ie, heterozy-
gous deﬁ  ciency in both parents, or neonatal purpura fulmi-
nans in a previous pregnancy). In such a case, prophylactic 
protein C replacement after elective cesarian section in the 
34th gestation week has been suggested, as fetal retinal 
vein thrombosis usually occurs late in pregnancy (Manco-
Johnson et al 1992; Hattenbach et al 1999; Barnes et al 2002). 
Another theoretical approach may be a prophylactic protein 
C substitution of the (heterozygous) mother to high normal 
levels, assuming the possibility of a transplacentar crossing 
of protein C, but this has never been performed in practice.
Long-term therapy of patients with homozygous protein C 
deﬁ  ciency after the initial symptoms have resolved is performed 
with oral anticoagulation, supplemented with protein C zymogen 
concentrates in high-risk situations (DeStefano et al 1993).
Heterozygous protein C deﬁ  ciency
In patients with a heterozygous protein C deﬁ  ciency only one 
chromosome 2 carries a mutation in the protein C gene, the 
other induces the synthesis of normal protein C (Grifﬁ  n et al 
1991; Lane et al 1997). Therefore, such patients have about 
half of the normal protein C activity in their plasma. The 
incidence in healthy blood donors is about 0.4% (Milletich 
et al 1987). In 5% of patients with venous thromboembolism 
a heterozygous protein C deﬁ  ciency is found.
Venous thromboembolism is the major clinical manifes-
tation of heterozygous protein C deﬁ  ciency (Pabinger et al 
1994; Pabinger and Schneider 1996; Sanson et al 1999). A 
prospective study on (primary asymptomatic) patients with 
heterozygous protein C deﬁ  ciency found an elevated risk for 
thrombosis of 2.5% per year (5.9-year observation period) 
(Pabinger et al 1992). Other epidemiological studies found 
similar rates (Bovill 1989; Sanson 1999). Thrombosis occurs 
often spontaneously, most frequently in the veins of the 
lower extremity, but also in the brain, the mesenteric, or renal 
veins. The typical age of the ﬁ  rst manifestation is between 
25 and 40 years, earlier in women than in men (Grifﬁ  n et al 
1981; Bertina et al 1982; Bovill et al 1989; Allaart et al 
1993; Goodwin et al 1995; Mustafa et al 1998).
Another manifestation of heterozygous protein C 
deﬁ  ciency is coumarin–induced skin necrosis. This symptom 
occurs during the ﬁ  rst days after initiation of a therapy with 
vitamin K antagonists, and its morphology resembles that of 
purpura fulminans: microvascular thrombosis and inﬂ  amma-
tion (Broekmans et al 1983). It was ﬁ  rst described in 1943 
(Flood et al 1943), and, untreated, it can lead to large necrosis 
needing surgical debridement. A report on the coincidences of 
Table 4 Therapeutic options for severe (homozygous or mixed 
heterozygous) protein C deﬁ  ciency
•   Plasma-derived protein C zymogen concentrates 
(Ceprotin®, Protexel®)
60–80 IU/kg body weight slow i.v. bolus every 6 hours
(maximum rate 2 mL/min in adults or 0.2 ml/min in children 10 kg)
Target: post-infusion plasma protein C activity 1.0 IU/mL,
pre-infusion plasma protein C activity 0.25 IU/mL
Alternative regimen:
100 U/kg slow i.v. bolus, followed by 10 IU/kg/h continuous infusion
Target: plasma protein C activity 1.0 IU/mL
•  Fresh frozen plasma
20–30 mL/kg i.v. every 6 hours
•   Activated human protein C – drotrecogin alpha activated 
(Xigris®)
20 μg/kg/hour for 10 hours?
not approved for substitution therapy of congenital protein C deﬁ  ciency
After symptoms have resolved:
Vitamin K antagonist therapy – warfarin
Slow initiation, overlapping with protein C substitutionBiologics: Targets & Therapy 2008:2(2) 291
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coumarin-induced skin necrosis and heterozygous protein C 
deﬁ  ciency in 1983 (Broekmans et al 1983) led to the descrip-
tion of the pathophysiology of this phenomenon: the reason 
is the short half-life of protein C in comparison with other 
procoagulatoric vitamin K dependent coagulation factors (ie, 
F II, IX, X) (Kelly and O`Malley 1979). Because of the lower 
initial protein C levels in such patients the protein C activity 
decreases faster and to lower levels than the procoagulatoric 
proteins, therefore causing a procoagulatoric state in the ﬁ  rst 
days of such a therapy. It is unclear why this phenomenon 
occurs in the microcirculation of the skin. However, the 
clinical and histological manifestation resembles that of 
the lesions of neonatal purpura fulminans in homozygous 
protein C deﬁ  ciency, and of infection-induced purpura ful-
minans (for example in meningococcal sepsis) (Shimamura 
et al 1983). All these states are associated with a localized 
breakdown of the protein C system in the microcirculation, 
and respond well to protein C replacement therapy.
Treatment of a heterozygous protein C deﬁ  ciency state is 
usually performed with long-term anticoagulation in cases of 
thromboembolism. Vitamin K antagonist therapy should be 
initiated slowly and with low doses under ongoing heparin 
treatment to avoid aggravation of the hypercoagulable state. 
However, it can be expected that the new anticoagulants 
currently under development (oral thrombin or factor 
Xa inhibitors) will overcome these problems. In patients 
without thromboembolism no therapy is necessary, but in 
situations with additional prothrombotic risk (for example 
immobilization, hormone replacement, surgery, pregnancy) 
low-molecular-weight heparins in a prophylactic dose should 
be consequently given (Table 5).
In cases complicated by endogenous or exogenous factors 
forbidding anticoagulant therapy, short-term substitution 
therapy with protein C should be considered: plasma-derived 
protein C zymogen concentrates have been used frequently 
for this purpose (Schramm et al 1993; Lewandowski and 
Zawilska 1994; Toupance et al 1994; Goodwin et al 1995; 
Richards et al 1997; Tardy-Poncet et al 2001), but there 
are also reports on the use of drotrecogin alpha (activated) 
(Sugimoto et al 1997; Sekiyama et al 2003).
Protein C concentrates 
for replacement therapy 
of protein C deﬁ  ciency
Ceprotin®
Ceprotin® is a highly puriﬁ  ed plasma-derived concentrate of 
human protein C zymogen. The product has been developed 
since 1990 by the pharmaceutical company Immuno Ag, 
Vienna, Austria, and introduced into clinical trials and 
international approval by Baxter Healthcare Corp. Today, it 
is produced by Baxter AG, Vienna. Ceprotin® is produced 
from frozen human plasma, fulﬁ  lling the highest levels of 
international quality standards, and tested negative for HIV, 
hepatitis A, B and C virus, and parvovirus B19 by serologi-
cal and speciﬁ  c polymerase chain reactions. The production 
process includes several anion exchange chromatography 
steps, and ﬁ  nal puriﬁ  cation is performed with immunoadsorp-
tion on a murine monoclonal antibody to human protein C. 
Virus inactivation steps include vapor heating and treatment 
with polysorbate 80.
Ceprotin® is delivered as a sterile lyophilized powder, 
bottled in glass vials containing 500 or 1000 international 
units (IU) of protein C. One IU corresponds to the measured 
protein C activity in 1 mL of normal human plasma. It is 
reconstituted with sterile water for injections, the product 
contains human protein C with a high specific activity 
(200 IU/mg protein). The content of activated protein C is 
negligible. The content of other vitamin K dependent factors 
is below 1 IU/100 IU protein C. Additionally, 1 vial with 500 
IU protein C contains 40 mg human albumin, 44 mg sodium 
chloride, and 22 mg trisodium-citrate. Ceprotin® is approved 
by the European and US authorities for the treatment of 
severe congenital protein C deﬁ  ciency, ie, for neonatal 
purpura fulminans and for patients with coumarin-induced 
skin necrosis. It can be used in such patients for short-term 
Table 5 Therapeutic options for heterozygous protein C 
deﬁ  ciency
Asymptomatic carrier
No long-term therapy
Prolonged / intensiﬁ  ed prophylaxis of thromboembolic events (with LMWH) 
in risk situations
Patients with ﬁ  rst thromboembolic event
Therapeutic (full-dose) anticoagulation with LMWH
Overlapping slow initiation of warfarin (target INR 2.0–3.0) for 6–12 months
Recurrent thromboembolic events
Therapeutic (full-dose) anticoagulation with LMWH
Overlapping slow initiation of long-term warfarin therapy (target INR 
2.0–3.0)
Cases of coumarin-induced skin necrosis
Therapeutic (full-dose) anticoagulation with LMWH or UFH
Protein C concentrate (Ceprotin® initial dose 60 IU/kg every 6 h)
Target plasma protein C activity: post-infusion 1.0 IU/mL and pre-infusion 
0.25 IU/mL
Drotrecogin alpha activated (not approved)
overlapping slow initiation of warfarin therapy (target INR 2.0–3.0)
Abbreviations: INL, international normalized ratio; LMWH = low molecular weight 
heparin; UFH = unfractionated (standard) heparin.Biologics: Targets & Therapy 2008:2(2) 292
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prophylaxis when surgery is required, during the initiation 
of coumarin therapy, when coumarin therapy is not sufﬁ  cient 
to resolve the symptoms or when coumarin therapy is not 
feasible for other reasons.
The lyophilized material has a shelf life of at least 2 
years when stored at 4 °C. The dissolved concentrate should 
be injected immediately, the injection rate must not exceed 
2 mL/min in adults or 0.2 mL/min in children less then 10 kg 
weight. An initial dose of 60–80 IU/kg body weight should be 
useful in most cases of severe congenital protein C deﬁ  ciency. 
Plasma protein C activity should be measured before and 
after injections to determine recovery and half-life. Follow-
ing doses should be adjusted to obtain post-infusion plasma 
protein C activity levels of about 1.0 IU/mL during the initial 
phase. Doses should be repeated every 6 hours during the 
acute phase of the symptoms, considering the shortened half-
life of protein C in such states. Protein C plasma levels should 
be measured before every infusion, whenever possible, and 
the Ceprotin® dose should be modiﬁ  ed to obtain pre-infusion 
plasma levels 0.25 IU/mL. After stabilization, protein C 
measurements can be reduced to twice daily, and Ceprotin® 
dose or interval can be modiﬁ  ed accordingly. Ceprotin® 
therapy should be continued until skin lesions and coagu-
lopathy have resolved and the patient is stable, and during an 
overlapping alternative therapy (warfarin) until international 
normalized ratio (INR) is in the desired range.
Even a subcutaneous application of this substance can 
be effective as a salvage or maintenance therapy in patients 
with poor venous access. Experimental data and clinical 
reports demonstrated the feasibility of Ceprotin® therapy as 
a continuous infusion. The resolved drug is stable for at least 
32 hours at 30 °C in a syringe. Continuous infusion may have 
advantages in patients with sepsis and purpura fulminans, 
in whom the biological half-life of protein C is markedly 
reduced, and plasma protein C levels may drop between 
the injections of the concentrate. However, the substance 
is not yet approved for such an application. If the patient is 
switched to therapy with vitamin K antagonists, protein C 
replacement should be continued until stable anticoagulation 
is obtained. Dose modiﬁ  cations in patients with liver or renal 
dysfunction are not required, but coagulation parameters in 
such patients should be controlled frequently. No signs of 
overdosage have been noted until now.
Ceprotin® is identical with the physiological plasmatic 
protein C zymogen. The intravenous injection of Ceprotin® 
results in an immediate increase of the protein C concentration 
in the plasma. As studied in 12 asymptomatic patients with 
homozygous or double heterozygous protein C deﬁ  ciency, 
the administration of 1 IU Ceprotin®/kg body weight resulted 
in a median increase of plasma protein C activity of 1.4 % 
(0.014 IU/mL; range 0.005–0.017 IU/mL). The individual 
half-lives of protein C vary between 4.4 and 15.9 hours 
(median 10–12 hours). The individual in vivo recovery var-
ied between 20.4% and 83.2% (median 68.5%). In patients 
with acute thrombosis, with purpura fulminans, sepsis, or 
disseminated intravascular coagulopathy, the half-life and 
the recovery were profoundly lower (1.1 and 1.5 hours in 2 
newborns with congenital purpura fulminans).
Ceprotin® has an excellent safety proﬁ  le. No cases of 
transmission of microorganisms have been observed. Similar 
to other intravenous protein preparations, allergic or hyper-
sensitive reactions cannot be excluded completely. Ceprotin® 
may contain trace amounts of heparin. Therefore, in patients 
with heparin hypersensitivity, allergic reactions or a drop in 
platelet count (heparin-associated thrombocytopenia) can 
be observed. When Ceprotin® is used in patients with severe 
protein C deﬁ  ciency, the formation of inhibiting alloantibod-
ies cannot be completely excluded (as in severe hemophiliacs 
treated with factor VIII concentrates), but has not yet been 
observed. Although Ceprotin® has been used in the treatment 
of pregnant women with protein C deﬁ  ciency without any 
side effects, this has not been studied in controlled trials. 
No information is available on the possible excretion of 
Ceprotin® in the milk of lactating mothers. Therefore, the 
beneﬁ  ts of Ceprotin® in pregnant or breast-feeding women 
must carefully be balanced against potential risks.
Ceprotin® in congenital 
protein C deﬁ  ciency
Early case reports on the treatment of newborns with severe 
protein C deﬁ  ciency and neonatal purpura fulminans dem-
onstrated an impressive response to substitution therapy 
with protein C concentrates. These reports were the basis 
for the approval of Ceprotin®. Since then, several case 
reports on the use of Ceprotin® for substitution therapy 
of protein C deficiency states (either neonatal purpura 
fulminans or coumarin-induced skin necrosis) have been 
published (Dreyfus et al 1991, 1995; Auberger 1992; 
Manco-Johnson et al 1992; Conard et al 1993; DeStefano 
et al 1993; Alhenc-Gelas et al 1995; Baliga et al 1995; 
Goodwin et al 1995; Muller et al 1996). Obtaining venous 
access can be a considerable problem of long-term protein C 
replacement therapy. Several groups reported that subcutane-
ous application of Ceprotin® led to sufﬁ  cient pharmacokinetic 
results (Minford et al 1996; Sanz-Rodriugez et al 1999; 
Mathias et al 2004).Biologics: Targets & Therapy 2008:2(2) 293
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Coumarin-induced skin necrosis
Several reports on beneﬁ  cial effects of protein C replacement 
in patients with coumarin-induced skin necrosis have been 
published (Schramm et al 1993; Lewandowski and Zawilska 
1994; Gatti et al 2003). An analysis of 8 patients, who received 
in total 78 infusions with 88,476 IU Ceprotin®, demonstrated 
that the treatment was safe and effective with an improvement 
of thrombosis/skin necrosis (unpublished data).
A retrospective surveillance program observed more than 10 
years of Ceprotin® use on 79 patients with protein C deﬁ  ciency 
of different origins, treated for acute episodes, short-term and 
long-term prophylaxis, and conﬁ  rmed the above mentioned 
safety and efﬁ  cacy data (unpublished data).
Sepsis and purpura fulminans
Several infections, especially meningococcal or 
pneumococcal infections in some susceptible patients, 
may lead to severe coagulopathy and typical skin lesions, 
resembling the phenotype of neonatal purpura fulminans 
(Figure 1). Histological studies of such lesions demon-
strated microvascular ﬁ  brin deposition and inﬂ  ammation, 
resulting from a local breakdown of the protein C system 
(Shimamura et al 1983). Early reports from 1995 demon-
strated an impressive improvement of such lesions and of 
coagulopathy after protein C replacement in such cases of 
infection-induced purpura fulminans (Rivard et al 1995). 
Several other publications have presented case series of 
pediatric and adult patients with severe sepsis, purpura ful-
minans, and consumption coagulopathy due to meningococ-
cal infections (Gerson et al 1993; Rivard et al 1995; Smith 
et al 1997; Favier et al 1998; Kreuz et al 1998; Rintalaa 
et al 1998; Ettingshausen et al 1999; Clarke et al 2000; 
Leclerc et al 2000; Rintalaa et al 2000; White et al 2000b; 
Fourrier et al 2003; Vaccarella et al 2003; Schellongowski 
et al 2006). All of these reported in part impressive success 
in these severely ill patients with extremely high bleeding 
risk. The mortality of the protein C-treated patients in these 
reports was very low in comparison with the mortality pre-
dicted by scoring systems like the Glasgow Meningococcal 
Prognostic Score. All authors describe very low plasma 
protein C levels at presentation and a fast resolution of the 
coagulopathy and normalization of the protein C levels after 
initiation of protein C zymogen substitution. The signs of 
purpura fulminans on the skin resolved quickly, as well as 
organ dysfunction. However, a considerable “publication 
bias” has to be assumed.
A randomized trial on the use of Ceprotin® in 40 pediatric 
patients with severe meningococcal sepsis and septic shock 
served as a dose-ﬁ  nding study (De Kleijn et al 2003). Due 
to the small number of patients no analysis of survival rates 
could be performed, but it could be shown that the protein 
C zymogen, infused with the concentrate, was converted 
to activated protein C in vivo. No side effects occurred. 
The study demonstrated the safety of Ceprotin® in a small 
collective of severely ill patients.
In summary, substitution of protein C in clinical states 
of acquired pronounced deﬁ  ciency, mostly presenting as 
purpura fulminans, consumption coagulopathy, or fulmi-
nant thrombosis/organ failure, can cause in part impressive 
improvement. Although the grade of scientiﬁ  c evidence is 
low due to the lack of controlled trials, and Ceprotin® is 
not approved for these indications, the off-label use could 
be considered in such patients, who otherwise have a high 
mortality.
Protexel®
Protexel® (LFB, Les Ulis, France) is a protein C zymogen 
concentrate, derived from human plasma (Radosevich et al 
2003). Plasma from unpaid blood donors collected after 
accurate donor selection and donation qualiﬁ  cation is used 
as the source. The puriﬁ  cation process is performed on the 
supernatant after initial cryoprecipitation, and includes three 
anion exchange chromatography puriﬁ  cation steps, the last 
coupled with heparin-sepharose afﬁ  nity chromatography. 
Virus inactivation is performed with solvent/detergent treat-
ment (1% polysorbate and 0.3% tri(n-butyl)phosphate). The 
process has been shown to effectively inactivate enveloped 
viruses such as hepatitis B virus, human immunodeﬁ  ciency 
virus and hepatitis C virus. This process yields a high-purity 
product with a speciﬁ  c activity of 215 IU protein C/mg total 
protein, bottled in vials containing 500 IU protein C. The 
content of factors II, VII, IX, protein S, and activated protein 
C is less than 0.01 IU/mL. The total protein concentration is 
0.27 g/L. No albumin is added for stabilization.
Animal studies revealed a favorable safety profile: 
no signs of thrombogenicity were observed, even at high 
doses. No adverse reactions, acute toxicity, or immunologic 
response were observed. The efﬁ  cacy of the virus inactivation 
procedure was tested with model viruses. Reconstituted 
Protexel® was stable up to 24 hours at room temperature.
The recommended dosing regimen of Protexel® is similar 
to that of Ceprotin®: for neonatal purpura fulminans or acute 
thrombosis in severe protein C deﬁ  ciency 60 IU/kg initial 
bolus, repeated 4 times daily, under monitoring of plasma 
protein C activity (aimed to minimal levels of 0.25 IU/mL), 
D-dimer, or prothrombin fragment 1 + 2.Biologics: Targets & Therapy 2008:2(2) 294
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A comprehensive report on the use of this concentrate in 
patients with inherited protein C deﬁ  ciency was by Dreyfus 
et al (2007). The authors performed a retrospective workup 
of 9 patients (5 male, 4 female, age 3 days to 52 years), 
treated in 7 centers in France for protein C deﬁ  ciency. Four 
patients had homozygous deﬁ  ciency, 1 double heterozygous, 
3 heterozygous, and 1 protein C deﬁ  ciency of unknown 
origin. Indications for therapy were neonatal purpura fulmi-
nans (n = 1), necrotic hematomas (n = 19), venous thrombo-
embolism (n = 2), and problems during vitamin K antagonist 
therapy (n = 5). Thirty courses of treatment were given, rang-
ing from 1 day to 33 months. In total, 914 infusions/883,110 
IU on 2006 cumulative exposure days to protein C concentrate 
from 26 different batches were performed. Recovery analysis 
demonstrated a post-infusion increase of protein C levels 
between 0.8 and 1.1% per kg body weight. Clinical response 
was sufﬁ  cient in all cases, as justiﬁ  ed by the investigators. 
The safety proﬁ  le was excellent; no untoward side effects 
were observed, even not high doses (up to 209 IU/kg/day). No 
abnormal bleeding occurred, and no evidence of blood-born 
infection transmission.
Drotrecogin alpha activated (Xigris®)
Drotrecogin alpha (activated) (Xigris®, Eli Lilly Co.) is avail-
able as is a recombinant analogue to the physiologic human 
activated protein C. It is approved for the adjunctive therapy 
of adult patients with severe sepsis. The recommended dose 
of Xigris® in this indication is 24 μg/kg/hour, given as a con-
tinuous intravenous infusion for a total duration of 96 hours. 
Xigris is not approved for the treatment of congenital protein C 
deﬁ  ciency, but single case reports suggest efﬁ  cacy. However, 
the optimal dose and duration of applications are not deﬁ  ned.
One paper has reported report on the use of recombinant 
activated protein C to treat an episode of purpura fulminans 
in a teenage girl with severe protein C deﬁ  ciency who had 
developed anaphylaxis to fresh-frozen plasma that was given 
in the past to treat recurrent episodes of purpura fulminans 
(Manco-Johnson et al 2004). Infusion of activated protein C 
(20 μg/kg/hour for 10 hours) reduced d-dimer levels from 
6450 to 847 ng/mL, indicating a control of coagulopathy, 
and reduced skin lesions. The teenager was then treated with 
heparin overlapping with warfarin for 4 days until the INR 
was more than 3.5 and the d-dimer level 230 ng/mL. At 
the end of the activated protein C infusion, all skin lesions 
of PF were resolved. There were no adverse reactions to 
activated protein C.
Another report was published by a Japanese group, who 
used another concentrate of activated protein C to treat a 
female newborn who developed purpura fulminans on the 
third day after birth due to homozygous protein C deﬁ  ciency 
(Nakayama et al 2000). Intravenous infusions of activated 
protein C markedly improved the necrotic skin lesions and 
enabled successful control of coagulopathy.
In conclusion, there is some evidence that activated 
protein C may also be effective in treating congenital pro-
tein C deﬁ  ciency. It may be used in emergency cases when 
Ceprotin® is not available.
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